FDA Approves 1st New Schizophrenia Drug in Decades
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
FDA Approves the First New Schizophrenia Drug in Decades
26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder. Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb ...
FDA Approves Potentially Groundbreaking Schizophrenia Drug
People living with schizophrenia will soon have a new and potentially groundbreaking treatment available. It’s called Cobenfy, and it’s the first new drug for the mental health condition to be ...
FDA approves new type of schizophrenia drug
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral medication that is manufactured by Bristol Myers Squibb in New Jersey.
FDA Approves First New Schizophrenia Drug In 30 Years: Cobenfy Offers Hope With Fewer Side Effects | Details
The FDA has approved Cobenfy, the first new schizophrenia treatment in 30 years, offering a novel approach with fewer side effects. Developed by Karuna Therapeutics, the drug is set to provide new hope for patients.
FDA Approves the First New Type of Schizophrenia Drug in Decades
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle movement, and sedation — that can cause patients to discontinue treatment.
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical company.
FDA Approves Revolutionary Schizophrenia Drug
In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name Cobenfy,
ABC News4d
FDA approves 1st new drug for schizophrenia in more than 30 years
The medication, Cobenfy, combines two drugs and is taken as a twice-daily pill. The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with ...
Becker's Hospital Review2d
FDA approves schizophrenia treatment
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
The Washington Post3d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione, director of FDA’s division of psychiatry, said in a statement. “This approval offers a ...
Today5d
FDA issues recall notices over 2 brands of pet food due to salmonella and listeria risk
Amid an ongoing pet food recall, the U.S. Food and Drug Administration (FDA) is urging pet owners not to give their dogs and cats certain food products from two different brands. Both the brands ...
Coventry Telegraph3d
Man arrested for sending 'sexual messages' to 14-year-old child in Coventry
A man has been arrested on suspicion of sending sexual messages to a child in Coventry. He was detained in Walsgrave on Monday (September 23). Officers arrested the 39-year-old man, who has not ...
Medical Xpress3d
FDA approves new kind of drug for schizophrenia
It is a severe, chronic mental illness that is often damaging to a person's quality of life," said Dr. Tiffany Farchione, director of psychiatry in the Office of Neuroscience in the FDA's Center ...